HMGN2 Antibody [F23H15] | Primary Antibodies

Application: Reactivity: Human

Lane 1: HL60, Lane 2: K562, Lane 3: Hela, Lane 4: SH-SY5Y

Usage Information

Dilution
WB1:1000-1:10,000 IHC1:250-1:500

Application
WB, IHC

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
9 kDa 18 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
HMGN2 Antibody [F23H15] detects endogenous levels of total HMGN2 protein.

Clone
F23H15

Synonym(s)
HMG17; HMGN2; Non-histone chromosomal protein HMG-17; High mobility group nucleosome-binding domain-containing protein 2

Background
HMGN2 (High Mobility Group Nucleosome‑binding domain 2) is a small, non‑histone chromosomal protein of the HMGN family that binds directly to the nucleosome core particle and modulates chromatin structure and function. It is widely expressed in multiple tissues and is recruited to nucleosomes by interacting with the acidic patch of the H2A–H2B dimer and with nucleosomal DNA near the dyad‑entry/exit regions, partially displacing linker histone H1 and altering nucleosome spacing and higher‑order folding. Through these interactions, HMGN2 influences chromatin accessibility and histone modification patterns, including the enhancement of certain histone acetylation marks, and thereby regulates the binding of transcription factors and the activity of transcriptional enhancers and promoters. HMGN2 also associates with transcription factors such as Lef‑1 and Pitx2, and can inhibit their DNA‑binding and transcriptional activation, positioning it as a chromatin‑linked modulator of lineage‑specific gene programs during development and differentiation. HMGN2 is detectable in the extracellular milieu under inflammatory or cytotoxic conditions and can act as an effector‑type protein in immune cells, where it has been reported to inhibit tumor‑cell proliferation and migration, induce apoptosis, and sensitize cancer cells to chemotherapeutic agents. Altered HMGN2 expression or localization is observed in several cancers, where it can correlate with reduced proliferation, migration, and tumor growth, and HMGN2‑deficiency studies further link it to changes in innate immune responses and chromatin‑dependent macrophage reprogramming.

Background

HMGN2 (High Mobility Group Nucleosome‑binding domain 2) is a small, non‑histone chromosomal protein of the HMGN family that binds directly to the nucleosome core particle and modulates chromatin structure and function. It is widely expressed in multiple tissues and is recruited to nucleosomes by interacting with the acidic patch of the H2A–H2B dimer and with nucleosomal DNA near the dyad‑entry/exit regions, partially displacing linker histone H1 and altering nucleosome spacing and higher‑order folding. Through these interactions, HMGN2 influences chromatin accessibility and histone modification patterns, including the enhancement of certain histone acetylation marks, and thereby regulates the binding of transcription factors and the activity of transcriptional enhancers and promoters. HMGN2 also associates with transcription factors such as Lef‑1 and Pitx2, and can inhibit their DNA‑binding and transcriptional activation, positioning it as a chromatin‑linked modulator of lineage‑specific gene programs during development and differentiation. HMGN2 is detectable in the extracellular milieu under inflammatory or cytotoxic conditions and can act as an effector‑type protein in immune cells, where it has been reported to inhibit tumor‑cell proliferation and migration, induce apoptosis, and sensitize cancer cells to chemotherapeutic agents. Altered HMGN2 expression or localization is observed in several cancers, where it can correlate with reduced proliferation, migration, and tumor growth, and HMGN2‑deficiency studies further link it to changes in innate immune responses and chromatin‑dependent macrophage reprogramming.

References
https://pubmed.ncbi.nlm.nih.gov/35872015/ https://pubmed.ncbi.nlm.nih.gov/25530340/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%